These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24335994)

  • 1. IV enoxaparin in pediatric and cardiac ICU patients.
    Cies JJ; Santos L; Chopra A
    Pediatr Crit Care Med; 2014 Feb; 15(2):e95-103. PubMed ID: 24335994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
    Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
    Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with intravenous enoxaparin in critically ill infants and children.
    Crary SE; Van Orden H; Journeycake JM
    Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
    Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
    Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
    Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
    Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
    J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H; Faraklas I; Saffle J; Cochran A
    J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved.
    Nunez JM; Becher RD; Rebo GJ; Farrah JP; Borgerding EM; Stirparo JJ; Lauer C; Kilgo P; Miller PR
    Am Surg; 2015 Jun; 81(6):605-9. PubMed ID: 26031274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
    Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A; Held K; Oschman A
    Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
    Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA
    J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
    J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
    Aslam MS; Sundberg S; Sabri MN; Cooke D; Lakier JB
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):187-90. PubMed ID: 12357518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK; Shelton CM; Sahni JK; Christensen ML
    Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.